

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

RESPONSE UNDER 37 CFR 1.111
Examining Group 1617
Patent Application
Docket No. GJE-6757C1
Serial No. 10/617,847

September 11, 2007
David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Layla Soroush
Art Unit : 1617
Applicant : Hazel Judith Bardsley *et al.*
Serial No. : 10/617,847
Conf. No. : 7988
Filed : July 10, 2003
For : New Therapeutic Use of 4-(2-Fluorophenyl)-6- Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

RESPONSE UNDER 37 CFR 1.111

Sir:

A Petition and Fee for a two-month Extension of Time is being authorized with the electronic filing of this paper.

In response to the Office Action dated April 11, 2007, the following remarks are respectfully presented.

Remarks/Arguments follow the amendment sections of this paper.